{"filing":{"accession_number":"0001628280-26-041962","cik":"0001411685","ticker":"VTGN","company_name":"Vistagen Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"vtgn-20260609.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026041962/vtgn-20260609.htm"},"events":[{"id":6062,"run_id":5322,"accession_number":"0001628280-26-041962","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Vistagen announced that its fasedienol nasal spray clinical program has achieved minimum patient exposures per ICH E1 regulatory standards for long-term treatment drugs. This represents a material clinical development milestone that advances the program toward regulatory submission and approval, affecting investor assessment of the company's pipeline progress and regulatory pathway. While not fitting the more specific event categories, this clinical achievement is material to a biopharmaceutical company's prospects.","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5637,"accession_number":"0001628280-26-041962","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Vistagen announced that its fasedienol nasal spray clinical program has achieved minimum patient exposures per ICH E1 regulatory standards for long-term treatment drugs. This represents a material clinical development milestone that advances the program toward regulatory submission and approval, affecting investor assessment of the company's pipeline progress and regulatory pathway. While not fitting the more specific event categories, this clinical achievement is material to a biopharmaceutical company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T21:06:09.320549+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5637,"accession_number":"0001628280-26-041962","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Vistagen announced that its fasedienol nasal spray clinical program has achieved minimum patient exposures per ICH E1 regulatory standards for long-term treatment drugs. This represents a material clinical development milestone that advances the program toward regulatory submission and approval, affecting investor assessment of the company's pipeline progress and regulatory pathway. While not fitting the more specific event categories, this clinical achievement is material to a biopharmaceutical company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T21:06:09.320549+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-06-09"}]}